$An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk$

An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk

Saved in:

Bibliographic Details
Main Authors:	Bin Xue, Yifan Liu, Min Zhang, Gangfeng Xiao, Xiu Luo, Lili Zhou, Shiguang Ye, Yan Lu, Wenbin Qian, Li Wang, Ping Li, Aibin Liang, Sihan Zhou, Xiuyuan Hao
Format:	Article
Language:	English
Published:	Wolters Kluwer 2025-01-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000003343
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical outcomes of chimeric antigen receptor T-cell therapy following autologous hematopoietic stem cell transplantation in 38 patients with refractory/relapsed primary or secondary central nervous system lymphoma
by: Jiaying Wu, et al.
Published: (2024-11-01)

CURRENT ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
by: Luca Castagna, et al.
Published: (2015-02-01)

Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma
by: Narendranath Epperla, et al.
Published: (2025-01-01)

Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
by: Xu Yang, et al.
Published: (2024-12-01)

Updates on Chimeric Antigen Receptor T-Cells in Large B-Cell Lymphoma
by: Khalil Saleh, et al.
Published: (2024-12-01)

EAM conditioning regimen followed by autologous hematopoietic Stem Cell Transplantation for relapsed, refractory and high risk lymphomas
by: Mohamed BEKADJA, et al.
Published: (2014-08-01)

Hepatic T cell lymphoma after chimeric antigen receptor T cell therapy for myeloma
by: Joshua Mehr, et al.
Published: (2024-12-01)

Against the odds: Managing pediatric relapsed/refractory Hodgkin lymphoma with autologous stem cell transplant in resource-limited settings
by: Sanjana Sarangarajan, et al.
Published: (2024-01-01)

Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults
by: Maike Breidenbach, et al.
Published: (2025-01-01)

Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma
by: Hui-Ju Hsieh, et al.
Published: (2025-03-01)

Single-cell transcriptomic and spatial analysis reveal the immunosuppressive microenvironment in relapsed/refractory angioimmunoblastic T-cell lymphoma
by: Mengyan Zhu, et al.
Published: (2024-12-01)

Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration
by: Alice Sýkorová, et al.
Published: (2024-09-01)

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients
by: Evgeny Klyuchnikov, et al.
Published: (2011-01-01)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
by: Eugenio Galli, et al.
Published: (2021-10-01)

Outcome of autologous bone marrow transplant in patients with relapsed and refractory diffuse large B-cell lymphoma in relation with prognostic factor: A single-center experience
by: Fawaz Salim Yousif, et al.
Published: (2024-12-01)

Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma
by: Giulio Cassanello, et al.
Published: (2024-12-01)

Chidamide plus R‐GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study
by: Guang‐Liang Chen, et al.
Published: (2024-08-01)

Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
by: Elise A. Chong, et al.
Published: (2025-02-01)

CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome
by: Yi Xiao, et al.
Published: (2020-05-01)

CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
by: Ugo Testa, et al.
Published: (2024-10-01)

Chimeric antigen receptor T-cell therapy in autoimmune diseases
by: Jie Liu, et al.
Published: (2024-11-01)

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas
by: Gohar S. Manzar, et al.
Published: (2025-01-01)

Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium
by: Jessy Xinyi Han, et al.
Published: (2025-02-01)

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies
by: Haiqiong Zheng, et al.
Published: (2024-11-01)

Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients
by: Gianmarco Bagnato, et al.
Published: (2024-01-01)

OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT
by: Ulrike Bacher, et al.
Published: (2023-04-01)

CD19‐targeting chimeric antigen receptor T‐cell therapy is safe and effective for intra‐cardiac B cell non‐Hodgkin lymphoma
by: Daniel H. Chen, et al.
Published: (2024-12-01)

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
by: Narendranath Epperla, et al.
Published: (2024-11-01)

Chimeric antigen-receptor (CAR) T cells: The revolution of the cell and personalized therapy for cancer
by: Javier Briones-Meijide
Published: (2019-11-01)

A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
by: Margaret Hux, et al.
Published: (2016-10-01)

“The End of the Golden Weather”: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors
by: Brian T. Grainger, et al.
Published: (2024-11-01)

Cytokine release syndrome after chimeric antigen receptor T cell therapy in patients with diffuse large B-cell lymphoma: a systematic review
by: Andressa Rodrigues dos Santos, et al.
Published: (2024-12-01)

Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2
by: Michael Wang, et al.
Published: (2020-10-01)

A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy
by: Xiumin Li, et al.
Published: (2024-11-01)

AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE LYMPHOMAS
by: Giuseppe Visani, et al.
Published: (2012-11-01)

First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomas
by: Pedro Justicia-Lirio, et al.
Published: (2024-12-01)

Chemo-free salvage treatment outperforms traditional chemotherapy in advanced lines of relapsed/refractory subcutaneous panniculitis-like T-cell lymphoma
by: Chao Chen, et al.
Published: (2024-12-01)

Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy
by: C. Carcopino, et al.
Published: (2024-12-01)

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
by: Yelei Guo, et al.
Published: (2016-01-01)

Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
by: Pavel Otáhal, et al.
Published: (2016-04-01)